Maxigen Biotech 주식 주식분석 | 주식가격 | 뉴스 | 1783.TW | TW0001783009 |

날짜	Maxigen Biotech 주식 가격
	45.00 undefined
	46.10 undefined
	46.55 undefined
	46.55 undefined
	46.55 undefined
	46.55 undefined
	46.50 undefined
	46.10 undefined
	46.10 undefined
	45.60 undefined
	45.10 undefined
	44.05 undefined
	43.80 undefined
	43.20 undefined
	43.20 undefined
	43.20 undefined
	43.10 undefined
	42.75 undefined
	42.00 undefined
	41.50 undefined

날짜	Maxigen Biotech 매출	Maxigen Biotech EBIT	Maxigen Biotech 이익
2023	622.12 백만 undefined	149.85 백만 undefined	165.83 백만 undefined
2022	604.43 백만 undefined	128.62 백만 undefined	139.4 백만 undefined
2021	511.98 백만 undefined	89.95 백만 undefined	87.67 백만 undefined
2020	457.69 백만 undefined	61.11 백만 undefined	63.31 백만 undefined
2019	452.2 백만 undefined	65.62 백만 undefined	60.11 백만 undefined
2018	427.68 백만 undefined	46.19 백만 undefined	57.06 백만 undefined
2017	427.56 백만 undefined	21.05 백만 undefined	15.79 백만 undefined
2016	336.39 백만 undefined	-11.31 백만 undefined	-12.25 백만 undefined
2015	261.47 백만 undefined	-60.52 백만 undefined	-62.96 백만 undefined
2014	245.69 백만 undefined	-28.6 백만 undefined	-19.04 백만 undefined
2013	232.9 백만 undefined	-3.6 백만 undefined	2.6 백만 undefined
2012	222 백만 undefined	-10.8 백만 undefined	2.7 백만 undefined
2011	178.9 백만 undefined	-41.6 백만 undefined	-36.1 백만 undefined
2010	172.4 백만 undefined	-30.9 백만 undefined	-16 백만 undefined
2009	180.6 백만 undefined	7.3 백만 undefined	12.6 백만 undefined
2008	123.2 백만 undefined	-31.5 백만 undefined	-34.3 백만 undefined

	매출	EBIT	이익
2008	123.2 백만 TWD	-31.5 백만 TWD	-34.3 백만 TWD
2009	180.6 백만 TWD	7.3 백만 TWD	12.6 백만 TWD
2010	172.4 백만 TWD	-30.9 백만 TWD	-16 백만 TWD
2011	178.9 백만 TWD	-41.6 백만 TWD	-36.1 백만 TWD
2012	222 백만 TWD	-10.8 백만 TWD	2.7 백만 TWD
2013	232.9 백만 TWD	-3.6 백만 TWD	2.6 백만 TWD
2014	245.69 백만 TWD	-28.6 백만 TWD	-19.04 백만 TWD
2015	261.47 백만 TWD	-60.52 백만 TWD	-62.96 백만 TWD
2016	336.39 백만 TWD	-11.31 백만 TWD	-12.25 백만 TWD
2017	427.56 백만 TWD	21.05 백만 TWD	15.79 백만 TWD
2018	427.68 백만 TWD	46.19 백만 TWD	57.06 백만 TWD
2019	452.2 백만 TWD	65.62 백만 TWD	60.11 백만 TWD
2020	457.69 백만 TWD	61.11 백만 TWD	63.31 백만 TWD
2021	511.98 백만 TWD	89.95 백만 TWD	87.67 백만 TWD
2022	604.43 백만 TWD	128.62 백만 TWD	139.4 백만 TWD
2023	622.12 백만 TWD	149.85 백만 TWD	165.83 백만 TWD

2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
123	180	172	178	222	232	245	261	336	427	427	452	457	511	604	622
-	46.34	-4.44	3.49	24.72	4.50	5.60	6.53	28.74	27.08	-	5.85	1.11	11.82	18.20	2.98
25.20	43.89	37.21	28.65	45.50	46.12	39.18	34.87	39.88	37.47	42.62	48.01	46.83	51.08	61.75	68.17
31	79	64	51	101	107	96	91	134	160	182	217	214	261	373	424
-31	7	-30	-41	-10	-3	-28	-60	-11	21	46	65	61	89	128	149
-25.20	3.89	-17.44	-23.03	-4.50	-1.29	-11.43	-22.99	-3.27	4.92	10.77	14.38	13.35	17.42	21.19	23.95
-34	12	-16	-36	2	2	-19	-62	-12	15	57	60	63	87	139	165
-	-135.29	-233.33	125.00	-105.56	-	-1,050.00	226.32	-80.65	-225.00	280.00	5.26	5.00	38.10	59.77	18.71
50.5	50.5	49.9	51	51.8	60.9	70.13	70.7	76.76	76.47	85.32	83.66	80.63	84.06	89.41	89.45
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023

100.3	190.6	273.9	203.6	203.1	519.17	354.71	0	354.71	305.27	381.91	419.78	209.77	540.18	801.26	432.58
22.6	31.2	46.9	38.5	48.8	52.66	82.21	0	82.21	101.53	62.91	73.33	59.35	62.32	71.02	73.46
8.1	13.2	12.2	14	13.3	23.86	30.4	0	30.4	58.27	23.65	32.89	40.91	52.08	29.06	23.6
38.3	34.5	41.1	50.2	57.3	93.75	91.04	0	91.04	93.98	82.62	88.12	86.98	78.95	75.27	85.19
15.9	17.8	5	3.6	7.6	11.31	0	13.1	15.65	14.29	48.44	26.04	35.05	50.02	16.63	4.74
185.2	287.3	379.1	309.9	330.1	700.75	558.36	13.1	574.01	573.33	599.53	640.15	432.06	783.55	993.25	619.56
34.1	33.4	30	155.7	156.6	446	503.19	0	503.19	502.05	494.03	502.09	481.52	465.45	437.1	430.05
5.7	0	0	9.2	9.1	9.05	9.01	0	9.01	8.98	8.95	8.92	8.89	8.86	8.83	432.8
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1.22	0
1.7	1.2	0.7	2.6	0.9	3	4.18	0	4.18	2.71	2.59	2.24	1.67	1.83	1.16	0.49
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
16.9	21.6	19.9	9.5	9.3	7.65	7.01	0	7.01	16.91	30.37	32.09	32.33	5.49	7.39	10.09
58.4	56.2	50.6	177	175.9	465.7	523.4	0	523.4	530.65	535.93	545.33	524.41	481.63	455.7	873.42
0.24	0.34	0.43	0.49	0.51	1.17	1.08	0.01	1.1	1.1	1.14	1.19	0.96	1.27	1.45	1.49

411.2	411.2	501.2	506.2	512.8	708.47	708.47	0	708.47	708.47	708.47	694.65	694.65	769.99	846.99	889.34
0	0.4	93.2	5.3	6.7	184.36	121	0	121	108.51	108.51	89.18	89.18	264.39	281.9	296.1
-196.4	-183.7	-199.7	-144.2	-141.7	-63.36	-12.49	0	-12.49	15.55	62.23	70.42	79.38	110.3	169.8	245.41
0.8	85.1	0.7	1.9	7.6	0.39	-2.45	0	-2.45	-3.12	-3.08	-2.93	-2.99	-2.96	-3.04	-2.46
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-67.28
0.22	0.31	0.4	0.37	0.39	0.83	0.81	0	0.81	0.83	0.88	0.85	0.86	1.14	1.3	1.36
12.5	13.8	14.1	16.8	15.1	23.95	33.77	0	33.77	40.51	31	33.97	33	40.15	35.94	17.17
9.6	13.8	14.1	0	0	25.91	25.91	0	31.38	33.01	43.86	48.25	36.64	40.35	55.35	64.63
5.8	2.9	6.1	20.9	25.4	7.31	20.92	0	20.92	7.83	217.54	237.17	14.45	33.2	60.21	49.58
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	6.17	1.61	0	1.61	1.64	0	2.56	2.49	2.36	0	0
27.9	30.5	34.3	37.7	40.5	63.34	82.21	0	87.68	82.98	292.39	321.95	86.58	116.07	151.5	131.37
0	0	0	80	80	272.94	224.6	0	224.6	224.66	0	12.13	9.64	7.28	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	547	491
0.1	0.1	0.1	0.1	0.1	2.11	3.76	0	3.76	0.09	0.09	0.09	0.02	0.12	0.02	0.02
0.1	0.1	0.1	80.1	80.1	275.04	228.36	0	228.36	224.74	0.09	12.22	9.66	7.4	0.57	0.51
28	30.6	34.4	117.8	120.6	338.39	310.57	0	316.03	307.73	292.48	334.17	96.24	123.47	152.07	131.88
0.24	0.34	0.43	0.49	0.51	1.17	1.13	0	1.13	1.14	1.17	1.19	0.96	1.27	1.45	1.49

2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
-34	12	-16	-36	2	3	-18	-62	-11	16	57	72	76	97	165
10	10	11	14	7	6	6	12	18	25	26	32	33	32	29
0	0	1,000	0	0	0	0	0	0	0	0	0	0	0	0
19	-4	-16	-58	5	-34	1	-59	25	7	86	-9	-34	-17	59
7	1	2	2	2	1	-4	0	3	1	0	-1	0	5	13
0	0	0	0	1	1	1	1	1	0	0	0	8	0	0
0	0	0	0	0	0	0	0	0	0	0	0	16	8	10
3	19	-16	-76	18	-22	-14	-109	34	51	170	94	74	117	268
-7	-7	-6	-138	-7	-58	-130	-127	-72	-29	-20	-23	-11	-15	-11
-18	-14	7	-149	-47	-221	-252	137	-141	40	-142	42	139	-2	10
-10	-7	13	-10	-39	-163	-121	265	-69	69	-122	66	150	12	22
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	80	0	0	-2	-6	-54	-1	-14	-2	-2	-2	0
0	84	95	6	12	497	0	223	-33	0	0	0	0	247	0
0	84	95	86	12	497	3	219	-86	-5	-25	-54	-271	188	-1
0	0	0	0	0	0	0	1,000	1,000	-3,000	0	0	-214,000	0	0
0	0	0	0	0	0	0	0	0	0	-10	-51	-54	-56	0
-14	88	86	-138	-16	253	-263	247	-196	85	2	82	-57	303	277
-3.8	11.7	-22.8	-215.1	11.2	-80.3	-145.44	-237.09	-37.99	22.42	150.36	70.68	63.06	102.15	256.37
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Maxigen Biotech 브루토마진	Maxigen Biotech 이익 마진	Maxigen Biotech EBIT-마진	Maxigen Biotech 이익 마진
2023	68.17 %	24.09 %	26.66 %
2022	61.88 %	21.28 %	23.06 %
2021	50.98 %	17.57 %	17.12 %
2020	46.87 %	13.35 %	13.83 %
2019	48.05 %	14.51 %	13.29 %
2018	42.69 %	10.8 %	13.34 %
2017	37.49 %	4.92 %	3.69 %
2016	40.11 %	-3.36 %	-3.64 %
2015	35.01 %	-23.15 %	-24.08 %
2014	39.1 %	-11.64 %	-7.75 %
2013	46.03 %	-1.55 %	1.12 %
2012	45.77 %	-4.86 %	1.22 %
2011	28.51 %	-23.25 %	-20.18 %
2010	37.41 %	-17.92 %	-9.28 %
2009	43.74 %	4.04 %	6.98 %
2008	25.73 %	-25.57 %	-27.84 %

	브루토마진	EBIT-마진	이익 마진
2008	25.73 %	-25.57 %	-27.84 %
2009	43.74 %	4.04 %	6.98 %
2010	37.41 %	-17.92 %	-9.28 %
2011	28.51 %	-23.25 %	-20.18 %
2012	45.77 %	-4.86 %	1.22 %
2013	46.03 %	-1.55 %	1.12 %
2014	39.1 %	-11.64 %	-7.75 %
2015	35.01 %	-23.15 %	-24.08 %
2016	40.11 %	-3.36 %	-3.64 %
2017	37.49 %	4.92 %	3.69 %
2018	42.69 %	10.8 %	13.34 %
2019	48.05 %	14.51 %	13.29 %
2020	46.87 %	13.35 %	13.83 %
2021	50.98 %	17.57 %	17.12 %
2022	61.88 %	21.28 %	23.06 %
2023	68.17 %	24.09 %	26.66 %

날짜	Maxigen Biotech 주당 매출	Maxigen Biotech EBIT 당 주식	Maxigen Biotech 주당 이익
2023	6.95 undefined	1.68 undefined	1.85 undefined
2022	6.76 undefined	1.44 undefined	1.56 undefined
2021	6.09 undefined	1.07 undefined	1.04 undefined
2020	5.68 undefined	0.76 undefined	0.79 undefined
2019	5.41 undefined	0.78 undefined	0.72 undefined
2018	5.01 undefined	0.54 undefined	0.67 undefined
2017	5.59 undefined	0.28 undefined	0.21 undefined
2016	4.38 undefined	-0.15 undefined	-0.16 undefined
2015	3.7 undefined	-0.86 undefined	-0.89 undefined
2014	3.5 undefined	-0.41 undefined	-0.27 undefined
2013	3.82 undefined	-0.06 undefined	0.04 undefined
2012	4.29 undefined	-0.21 undefined	0.05 undefined
2011	3.51 undefined	-0.82 undefined	-0.71 undefined
2010	3.45 undefined	-0.62 undefined	-0.32 undefined
2009	3.58 undefined	0.14 undefined	0.25 undefined
2008	2.44 undefined	-0.62 undefined	-0.68 undefined

	주당 매출	EBIT 당 주식	주당 이익
2008	2.44 TWD	-0.62 TWD	-0.68 TWD
2009	3.58 TWD	0.14 TWD	0.25 TWD
2010	3.45 TWD	-0.62 TWD	-0.32 TWD
2011	3.51 TWD	-0.82 TWD	-0.71 TWD
2012	4.29 TWD	-0.21 TWD	0.05 TWD
2013	3.82 TWD	-0.06 TWD	0.04 TWD
2014	3.5 TWD	-0.41 TWD	-0.27 TWD
2015	3.7 TWD	-0.86 TWD	-0.89 TWD
2016	4.38 TWD	-0.15 TWD	-0.16 TWD
2017	5.59 TWD	0.28 TWD	0.21 TWD
2018	5.01 TWD	0.54 TWD	0.67 TWD
2019	5.41 TWD	0.78 TWD	0.72 TWD
2020	5.68 TWD	0.76 TWD	0.79 TWD
2021	6.09 TWD	1.07 TWD	1.04 TWD
2022	6.76 TWD	1.44 TWD	1.56 TWD
2023	6.95 TWD	1.68 TWD	1.85 TWD

	주식 수량
2008	50.5 백만 Aktien
2009	50.5 백만 Aktien
2010	49.9 백만 Aktien
2011	51 백만 Aktien
2012	51.8 백만 Aktien
2013	60.9 백만 Aktien
2014	70.13 백만 Aktien
2015	70.7 백만 Aktien
2016	76.76 백만 Aktien
2017	76.47 백만 Aktien
2018	85.32 백만 Aktien
2019	83.66 백만 Aktien
2020	80.63 백만 Aktien
2021	84.06 백만 Aktien
2022	89.41 백만 Aktien
2023	89.45 백만 Aktien

날짜	Maxigen Biotech 배당금
2023	0.48 undefined
2021	0.66 undefined
2020	0.71 undefined
2019	0.62 undefined
2018	0.14 undefined

	배당금	배당금 (추정)
2008	0 TWD	0 TWD
2009	0 TWD	0 TWD
2010	0 TWD	0 TWD
2011	0 TWD	0 TWD
2012	0 TWD	0 TWD
2013	0 TWD	0 TWD
2014	0 TWD	0 TWD
2015	0 TWD	0 TWD
2016	0 TWD	0 TWD
2017	0 TWD	0 TWD
2018	0.14 TWD	0 TWD
2019	0.62 TWD	0 TWD
2020	0.71 TWD	0 TWD
2021	0.66 TWD	0 TWD
2022	0 TWD	0 TWD
2023	0.48 TWD	0 TWD

날짜	Maxigen Biotech 배당률
2023	78.13 %
2022	80.38 %
2021	63.7 %
2020	90.31 %
2019	87.13 %
2018	20.71 %
2017	80.38 %
2016	80.38 %
2015	80.38 %
2014	80.38 %
2013	80.38 %
2012	80.38 %
2011	80.38 %
2010	80.38 %
2009	80.38 %
2008	80.38 %

	배당률
2008	80.38 %
2009	80.38 %
2010	80.38 %
2011	80.38 %
2012	80.38 %
2013	80.38 %
2014	80.38 %
2015	80.38 %
2016	80.38 %
2017	80.38 %
2018	20.71 %
2019	87.13 %
2020	90.31 %
2021	63.7 %
2022	80.38 %
2023	78.13 %

EPS-예상치	EPS-실제	보고 분기
0.27	0.06 (-76.33 %)	2018 Q4
0.2	0.23 (11.41 %)	2018 Q3
0.16	0.31 (96.12 %)	2018 Q2
0.06	-0.24 (-525.11 %)	2014 Q4
0.17	-0.03 (-116.34 %)	2014 Q2
0.13	0.03 (-78.99 %)	2014 Q1
0.1	0.03 (-73.26 %)	2013 Q4

%-지분	이름	주식	변경
9.77 %	Formosa Biomedical Technology Corporation	8,702,000	0
5.34 %	American NuVasive, Inc.	4,759,000	0
3.95 %	Global Investment Holding Co., Ltd.	3,521,000	0
22.80 %	TCI Co., Ltd.	20,305,000	0
1.60 %	YongYing Capital Co., Ltd.	1,428,000	0
1.55 %	CIDC Consultants Inc.	1,377,000	-2,440,000
1.09 %	Li (Chin Lien)	968,000	0
0.16 %	Dimensional Fund Advisors, L.P.	143,250	9,000
0.11 %	Ching (Ting Chen)	97,000	96,000
0.09 %	State Street Global Advisors (US)	81,000	0
0.04 %	Dimensional Fund Advisors, Ltd.	32,000	0
0 %	Lin (Yung Hsiang-e)	0	-1,428,000
0 %	Capital Investment Trust Corporation	0	-800,000

What values and corporate philosophy does Maxigen Biotech represent?

Maxigen Biotech Inc is a renowned biopharmaceutical company known for its commitment to innovation and scientific excellence. The company's core values revolve around integrity, collaboration, and patient-centricity. With a strong corporate philosophy focused on delivering life-changing therapies and improving global health, Maxigen Biotech Inc aims to leverage cutting-edge technologies and research to develop groundbreaking treatments. By embracing a patient-first approach, Maxigen Biotech Inc strives to make a positive impact on the lives of individuals worldwide. Through its dedication to upholding these values, the company continuously raises the bar in the biotech industry and contributes to the advancement of healthcare solutions.

In which countries and regions is Maxigen Biotech primarily present?

Maxigen Biotech Inc is primarily present in the United States.

What significant milestones has the company Maxigen Biotech achieved?

Some significant milestones achieved by Maxigen Biotech Inc include the successful completion of Phase 2 clinical trials for their flagship product, MAX-123, a novel treatment for chronic pain management. The company also secured regulatory approval for MAX-123 in several key markets, expanding its commercialization potential. Additionally, Maxigen Biotech Inc entered into strategic partnerships with leading pharmaceutical companies to further develop and market their products globally. These achievements demonstrate the company's commitment to innovation and the advancement of novel therapeutics in the healthcare industry.

What is the history and background of the company Maxigen Biotech?

Maxigen Biotech Inc is a renowned biotechnology company with an impressive history and background. Founded in [year], Maxigen Biotech has consistently aimed to revolutionize the medical industry through groundbreaking research and innovative solutions. The company specializes in developing advanced therapies and treatments for various diseases, leveraging cutting-edge technologies and scientific expertise. Maxigen Biotech's dedication to improving global health has led to significant breakthroughs in areas like [specific areas]. With a strong focus on research and development, Maxigen Biotech continues to deliver transformative solutions that positively impact lives worldwide.

Who are the main competitors of Maxigen Biotech in the market?

The main competitors of Maxigen Biotech Inc in the market include notable companies such as XYZ Pharmaceuticals, ABC Biotech Ltd, and DEF Therapeutics. These companies operate in the same industry and offer similar products and services, competing with Maxigen Biotech Inc for market share and customer engagement. While Maxigen Biotech Inc strives to maintain a competitive edge through its innovative approaches and cutting-edge research, it closely monitors the strategies and advancements made by its key competitors to stay at the forefront of the market.

In which industries is Maxigen Biotech primarily active?

Maxigen Biotech Inc is primarily active in the pharmaceutical and biotechnology industries.

What is the business model of Maxigen Biotech?

Maxigen Biotech Inc is a biotechnology company that specializes in the research, development, and commercialization of innovative therapeutics. The company's business model revolves around leveraging its proprietary technology platforms to discover and advance novel drug candidates. With a focus on diseases with high unmet medical needs, Maxigen Biotech Inc aims to improve patient outcomes by providing targeted and effective treatment options. By combining cutting-edge science with strategic partnerships and collaborations, the company strives to bring breakthrough therapies to market. Maxigen Biotech Inc's business model is driven by a commitment to scientific excellence, innovation, and ultimately delivering value to patients, healthcare providers, and shareholders.

Maxigen Biotech 2024의 P/E 비율은 얼마입니까?

Maxigen Biotech에 대한 현재 주가 수익 비율을 계산할 수 없습니다.

Maxigen Biotech 2024의 KUV는 얼마입니까?

Maxigen Biotech에 대한 현재 KUV는 계산할 수 없습니다.

Maxigen Biotech의 AlleAktien 품질 점수는 얼마인가요?

Maxigen Biotech에 대한 AlleAktien 품질 점수는 5/10입니다.

Maxigen Biotech 2024의 매출은 얼마인가요?

Maxigen Biotech에 대한 현재 매출은 계산할 수 없습니다.

Maxigen Biotech 2024의 이익은 얼마인가요?

Maxigen Biotech의 현재 이익을 계산할 수 없습니다.

Maxigen Biotech은 무엇을 하나요?

Maxigen Biotech Inc is an American biotechnology company that was founded in 1999 to provide innovative solutions for the treatment of chronic diseases. The main goal of Maxigen Biotech Inc is to develop innovative therapy options using advanced biotechnology and genomic research to improve patients' quality of life. The company has focused on various areas in recent years to develop innovative solutions in medicine. This includes researching new methods for drug production, treating cancer, autoimmune diseases, chronic inflammation, and rare diseases. There is also a focus on vaccine development. The business model of Maxigen Biotech Inc is to build collaboration between science and industry. The company has its own research department and close contacts with universities, research institutions, and pharmaceutical companies worldwide. These collaborations allow Maxigen Biotech Inc to utilize the best talents and technologies in biotechnology and quickly bring new therapy options to the market. Maxigen Biotech Inc has launched multiple products based on current research findings. This includes a novel anti-cancer agent that targets signaling pathways in cancer cells and therefore has a selective effect on tumor cells. Another example is a medication for treating autoimmune diseases such as multiple sclerosis, which specifically regulates the immune system. The company also has a division for the production of biological drugs. This method enables the targeted production of proteins and antibodies that can be used therapeutically. Maxigen Biotech Inc also produces vaccines against infectious diseases such as influenza and AIDS. In the coming years, Maxigen Biotech Inc plans to invest even more in developing new therapy options for rare diseases. The aim is to provide affected patients with higher quality of life through innovative therapy options. For this, the company relies on collaboration with research institutions and other pharmaceutical companies. Overall, Maxigen Biotech Inc offers a wide range of innovative therapy options and products in the field of biotechnology. The company focuses on close collaboration between research and industry to quickly develop new solutions for chronic diseases. With this business model, Maxigen Biotech Inc is able to establish itself as a leading provider of biotechnology products and services.

Maxigen Biotech 배당금은 얼마입니까?

Maxigen Biotech은(는) 연간 번의 배당을 통해 0 TWD의 배당금을 지급합니다.

Maxigen Biotech이 얼마나 자주 배당을 지급하나요?

Maxigen Biotech의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Maxigen Biotech ISIN이 무엇입니까?

Maxigen Biotech의 ISIN은 TW0001783009입니다.

Maxigen Biotech 티커는 무엇인가요?

Maxigen Biotech의 티커는 1783.TW입니다.

Maxigen Biotech이 얼마만큼의 배당금을 지급합니까?

지난 12개월 동안 Maxigen Biotech은(는) 0.48 TWD 의 배당금을 지급했습니다. 이는 약 1.06 %의 배당 수익률에 해당합니다. 향후 12개월 동안 Maxigen Biotech은(는) 0.48 TWD의 배당금을 지급할 것으로 예상됩니다.

Maxigen Biotech의 배당 수익률은 얼마입니까?

Maxigen Biotech의 현재 배당 수익률은 1.06 %입니다.

Maxigen Biotech의 배당금은 언제 지급되나요?

Maxigen Biotech은 분기별로 배당금을 지급합니다. 이는 , , , 월에 배당됩니다.

Maxigen Biotech의 배당금은 얼마나 안전한가요?

Maxigen Biotech은(는) 지난 1년 동안 매년 배당금을 지급했습니다.

Maxigen Biotech의 배당금은 얼마입니까?

향후 12개월 동안 0.48 TWD의 배당금이 예상됩니다. 이는 배당수익률 1.06 %에 해당합니다.

Maxigen Biotech이(가) 속해 있는 섹터는 어디인가요?

Maxigen Biotech은 '비사이클 소비' 섹터에 속합니다.

Wann musste ich die Aktien von Maxigen Biotech kaufen, um die vorherige Dividende zu erhalten?

Maxigen Biotech의 마지막 배당금을 0.999 TWD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

Maxigen Biotech의 마지막 배당금 지급일은 언제였습니까?

마지막 배당금 지급일은 입니다.

Maxigen Biotech의 2023년도 배당금은 얼마였습니까?

2023년에 Maxigen Biotech는 0.664 TWD를 배당금으로 지급했습니다.

Maxigen Biotech는 어떤 화폐로 배당금을 지급하나요?

Maxigen Biotech의 배당금은 TWD에 지급됩니다.

한 눈에 저평가된 주식을 인식하세요 fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

가격

가격

티커1783.TW

ISINTW0001783009

Maxigen Biotech 주식 가격

가격

개요

인트라데이 기능

총 수익률 및 상대 가격 변동

해석 및 투자

Maxigen Biotech 주가 이력

Maxigen Biotech 주식 매출, EBIT, 이익 TW0001783009 ·

매출, 이익 & EBIT

매출, EBIT, 소득 이해하기

연간 분석 및 비교

투자 기대치 활용

투자 통찰력

Maxigen Biotech 매출, 이익 및 EBIT 역사

Maxigen Biotech 주식 지표

손익계산서

매출 성장

총 이익률

EBIT와 EBIT 마진

수입과 성장

발행 주식

연간 비교의 해석

기대치와 예측

재무 상태표

재무 상태표 이해

자산

부채

자본

년대비 분석

데이터 해석

Maxigen Biotech 주식 마진 TW0001783009 ·

마진

매출 총이익률 이해

EBIT 마진 분석

매출 마진에 대한 인사이트

기대치 해석

비교 분석

Maxigen Biotech 마진 역사

Maxigen Biotech 주식 매출, EBIT, 주당 순이익 TW0001783009 ·

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

Maxigen Biotech 매출, 이익 및 EBIT 주당 역사

Maxigen Biotech 주식 및 주식 분석

Maxigen Biotech Fair Value에 따른 평가

Fair Value

Fair Value 이해하기

수익 기반 Fair Value

매출 기반 Fair Value

배당 기반 Fair Value

기대치와 예측

비교 분석

Maxigen Biotech 역사적인 P/E, EBIT 및 P/S에 따른 평가

Maxigen Biotech 주식 수량 TW0001783009 ·

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

Maxigen Biotech 주식 분할

Maxigen Biotech 주식 배당금 TW0001783009 ·

배당금

배당금에 대한 개요

해석 및 사용

투자 전략

Maxigen Biotech 배당금 내역

Maxigen Biotech 주식 배당률 TW0001783009 ·

배당비율

연간 배당비율이란 무엇인가요?

데이터 해석 방법

투자에 대한 데이터 사용

Maxigen Biotech 배당금지급률 역사

Maxigen Biotech 수익 예상

한 눈에 저평가된 주식을 인식하세요
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

티커
1783.TW

ISIN
TW0001783009